Essential Resources
Provider Information
From Our Sponsors
FDA VRBAC Meeting Cancelled, Fueling Concerns for Delays in 2025 Season Production
According to the CDC, influenza is responsible for 33 million illnesses, 430,000 hospitalizations, and 19,000 deaths so far this season.
COVID-19 2024-2025 Vaccines 33% Effective Against Hospitalization, ED Visits in Adults: Early Data
CDC midseason data suggest low COVID-19 vaccine efficacy in adults aged 18 to 64 years, with somewhat better impact on those aged 65 years and older.
WHO Recommends Flu Vaccine Composition for 2025-26 Northern Hemisphere Season as US HHS Cancels ACIP, VRBAC Meetings
Two official US vaccine planning meetings cancelled in February is an "unprecedented situation," said NFID medical director Robert Hopkins, Jr, MD.
17 Adult Vaccines: Who to Consider for Each
A review of 4 factors can help primary care clinicians with an initial decision about adult vaccination: Health, Age, Lifestyle, and Occupation, or HALO.
Vaccine Distrust, Emboldened During the Pandemic, Runs Deep: An Expert Perspective
Robert Hopkins, Jr, MD, says of official communications during the COVID-19 pandemic that not enough was explained to the public about policy shifts, leaving people wondering.
Two RSV Vaccines, One Savvy Patient who Asks, "Which One do You Recommend?"
RSV vaccines from Pfizer-BioNTech and Moderna for adults aged 60 years and older aren't that different, so which would you recommend if a patient asks?
The Legacy of Vaccine Hesitancy: From COVID-19 to Flu
Vaccine hesitancy became a public health threat during the COVID-19 pandemic that lingers now and has affected uptake of other essential immunizations.
Attitudes Toward Vaccines in the Chronic Conditions Community: Survey Highlights
Hesitancy about vaccination against dangerous communicable diseases remains a public health problem, particularly when the hesitant are living with immunocompromising conditions.
RSVPreF Reduces Risk of Severe RSV in Older, High-Risk Adults in Large Real-World Study
The new research augments data on efficacy of RSVPreF in older, high-risk adults that was not captured in phase 3 pivotal clinical trials, authors said.
10 Essential Vaccine Updates for Primary Care: Winter 2024-2025
From ACIP updates on age eligibility and research on vaccine efficacy to US adults' attitudes toward recommended shots, these 10 at-a-glance news briefs are must-reads for PCPs.
Flu, COVID-19, RSV Vaccine Uptake Low Among US Adults in 2024-2025 Season
Many unvaccinated adults reported intent to get vaccinated, according to early season estimates released in MMWR.
The RSV Vaccine Population was Narrowed for Good Reason, says Robert Hopkins, Jr, MD, Medical Director of the NFID
ACIP recommendations for the most appropriate older population for the RSV vaccine has shifted and the NFID medical director explains why.
New Data for Arexvy Show Vaccine Efficacy Through 3 RSV Seasons in Older Adults
Data on adults aged 60 years and older who received a single dose of the RSV vaccine indicate safety and reactogenicity consistent with the overall GSK phase 3 trial program.
COVID-19 Vaccines 2024-2025: Is America Ready and Willing?
COVID-19 vaccine myths of many types remain potent enough to raise public health experts' concerns about Americans' willingness to roll up sleeves this year.
